30% off. Use code SUMMER30 at checkout for 30% off for 12 months on Pro and Premium subscriptions. Subscribe now
United States Pharmaceuticals

Arvinas Inc (ARVN)

Track

Over the last 90 days, Arvinas Inc. has seen significant insider selling, with a net value of -$523,470. Executives have been net sellers, contributing to a negative net insider count. Total sell transactions amounted to $1,043,673, with no reported buy transactions from insiders during this period. The stock has experienced a 42.1% price decrease over 90 days.
Stock chart
Ticker: ARVN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Teel Randy
President and CEO
1 sale — total 19,962 USD
Sale 21 May 2026
Value US$1,834,875.53 | Price 206.12 | Shares 81,497
Proposed sale 21 May 2026
Value US$2,463,649.76 | Price 276.13 | Shares 84,085
Sale 11 May 2026
Value US$19,069.87 | Price 9.94 | Shares 1,919
Sale 11 May 2026
Value US$110,692.70 | Price 9.94 | Shares 11,139
Sale 11 May 2026
Value US$95,965.47 | Price 9.94 | Shares 9,657
Sale 11 May 2026
Value US$110,384.64 | Price 9.94 | Shares 11,108
Sale 11 May 2026
Value US$95,965.47 | Price 9.94 | Shares 9,657
Proposed sale 11 May 2026
Value US$114,677.73 | Price 10.11 | Shares 11,343
Proposed sale 11 May 2026
Value US$99,421.74 | Price 10.11 | Shares 9,834
Proposed sale 11 May 2026
Value US$114,364.32 | Price 10.11 | Shares 11,312
Proposed sale 11 May 2026
Value US$99,421.74 | Price 10.11 | Shares 9,834
Sale 18 Mar 2026
Value US$71,431.07 | Price 11.10 | Shares 6,435
Proposed sale 18 Mar 2026
Value US$72,324.22 | Price 12.01 | Shares 6,022
Buy 6 Mar 2026
Value US$268,070.00 | Price 13.40 | Shares 20,000
Sale 27 Feb 2026
Value US$154,881.18 | Price 13.14 | Shares 11,787
Sale 27 Feb 2026
Value US$249,203.28 | Price 13.24 | Shares 18,822
Sale 27 Feb 2026
Value US$62,069.12 | Price 13.24 | Shares 4,688
Proposed sale 27 Feb 2026
Value US$466,183.75 | Price 13.21 | Shares 35,297
Sale 23 Feb 2026
Value US$13,473.28 | Price 12.16 | Shares 1,108
Sale 23 Feb 2026
Value US$31,263.36 | Price 12.16 | Shares 2,571
Sale 23 Feb 2026
Value US$12,622.08 | Price 12.16 | Shares 1,038
Sale 23 Feb 2026
Value US$45,575.68 | Price 12.16 | Shares 3,748
Sale 23 Feb 2026
Value US$12,622.08 | Price 12.16 | Shares 1,038
Proposed sale 23 Feb 2026
Value US$43,896.77 | Price 12.16 | Shares 3,609
Proposed sale 23 Feb 2026
Value US$58,212.78 | Price 12.16 | Shares 4,786
Sale 13 Feb 2026
Value US$52,351.67 | Price 11.89 | Shares 4,403
Sale 13 Feb 2026
Value US$61,043.26 | Price 11.89 | Shares 5,134
Planned sale 13 Feb 2026
Value US$54,598.88 | Price 11.89 | Shares 4,592
Sale 13 Feb 2026
Value US$67,594.65 | Price 11.89 | Shares 5,685
Planned sale 13 Feb 2026
Value US$12,080.24 | Price 11.89 | Shares 1,016
Proposed sale 13 Feb 2026
Value US$54,607.52 | Price 11.89 | Shares 4,592
Proposed sale 13 Feb 2026
Value US$61,052.92 | Price 11.89 | Shares 5,134
Proposed sale 13 Feb 2026
Value US$67,605.35 | Price 11.89 | Shares 5,685
Proposed sale 13 Feb 2026
Value US$52,359.96 | Price 11.89 | Shares 4,403
Planned sale 7 Nov 2025
Value US$2,274.70 | Price 9.89 | Shares 230
Buy 22 Sep 2025
Value US$227,010.00 | Price 7.57 | Shares 30,000
Sale 24 Jun 2025
Value US$43,377.00 | Price 7.61 | Shares 5,700
Proposed sale 24 Jun 2025
Value US$43,593.00 | Price 7.35 | Shares 5,927
Sale 17 Jun 2025
Value US$19,346.67 | Price 7.49 | Shares 2,583
Sale 18 Mar 2025
Value US$74,372.22 | Price 8.59 | Shares 8,658
Proposed sale 18 Mar 2025
Value US$74,372.00 | Price 8.59 | Shares 8,658
Sale 24 Feb 2025
Value US$18,966.30 | Price 16.55 | Shares 1,146
Sale 24 Feb 2025
Value US$51,271.75 | Price 16.75 | Shares 3,061
Sale 24 Feb 2025
Value US$85,298.70 | Price 16.55 | Shares 5,154
Sale 24 Feb 2025
Value US$438,582.00 | Price 16.75 | Shares 26,184
Sale 24 Feb 2025
Value US$20,334.50 | Price 16.75 | Shares 1,214
Sale 24 Feb 2025
Value US$27,539.20 | Price 16.55 | Shares 1,664
Sale 24 Feb 2025
Value US$123,213.00 | Price 16.75 | Shares 7,356
Proposed sale 24 Feb 2025
Value US$150,730.00 | Price 16.71 | Shares 9,020
Proposed sale 24 Feb 2025
Value US$523,801.00 | Price 16.71 | Shares 31,338
Proposed sale 24 Feb 2025
Value US$70,230.00 | Price 16.69 | Shares 4,207
Sale 7 Nov 2024
Value US$6,396.39 | Price 27.69 | Shares 231
Proposed sale 20 May 2024
Value US$1,650,000.00 | Price 33.00 | Shares 50,000
Proposed sale 16 May 2024
Value US$1,155,000.00 | Price 33.00 | Shares 35,000
Proposed sale 15 May 2024
Value US$835,100.00 | Price 33.40 | Shares 25,000
Proposed sale 13 May 2024
Value US$480,000.00 | Price 32.00 | Shares 15,000
Sale 23 Feb 2024
Value US$79,937.95 | Price 47.05 | Shares 1,699
Sale 23 Feb 2024
Value US$244,471.80 | Price 47.05 | Shares 5,196
Sale 23 Feb 2024
Value US$80,079.10 | Price 47.05 | Shares 1,702
Sale 23 Feb 2024
Value US$80,032.05 | Price 47.05 | Shares 1,701
Sale 8 Nov 2023
Value US$3,904.45 | Price 17.05 | Shares 229
Sale 11 Aug 2023
Value US$32,288.52 | Price 24.39 | Shares 1,324
Sale 1 Mar 2023
Value US$173,577.34 | Price 29.53 | Shares 5,878
Sale 1 Mar 2023
Value US$51,529.85 | Price 29.53 | Shares 1,745
Sale 1 Mar 2023
Value US$31,036.03 | Price 29.53 | Shares 1,051
Sale 12 Aug 2022
Value US$86,794.45 | Price 68.99 | Shares 1,258
Planned sale 14 Apr 2022
Value US$720,887.94 | Price 67.03 | Shares 10,754
Planned sale 14 Apr 2022
Value US$469,355.60 | Price 66.07 | Shares 7,104
Planned sale 14 Apr 2022
Value US$202,372.31 | Price 65.24 | Shares 3,102
Planned sale 11 Mar 2022
Value US$1,050,000.00 | Price 70.00 | Shares 15,000
Sale 4 Mar 2022
Value US$55,563.86 | Price 63.94 | Shares 869
Sale 4 Mar 2022
Value US$101,856.42 | Price 63.94 | Shares 1,593
Sale 4 Mar 2022
Value US$385,174.56 | Price 63.94 | Shares 6,024
Planned sale 15 Feb 2022
Value US$7,658.00 | Price 76.58 | Shares 100
Planned sale 15 Feb 2022
Value US$22,740.00 | Price 75.80 | Shares 300
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-22 2026-05-21 S Sale
Teel Randy

President and CEO

Executive Director
81,497 +28.1%
206.12
US$1,834,876 		81,497 +28.1% 206.12 US$1,834,876
2026-05-20 2026-05-21 PrS Proposed sale
Randy Teel

Officer; Director

Executive Director
84,085
276.13
US$2,463,650 		84,085 276.13 US$2,463,650
2026-05-13 2026-05-11 S Sale
3.8
Loomis David K

VP, Chief Accounting Officer

Officer
19,369 -36.3%
55.45
US$4,649,142 		19,369 -36.3% 55.45 US$4,649,142
2026-05-13 2026-05-11 S Sale
3.1
Saik Andrew

Chief Financial Officer

Officer
11,139 -5.5%
9.94
US$110,693 		11,139 -5.5% 9.94 US$110,693
2026-05-13 2026-05-11 S Sale
3.6
Cacace Angela M

Chief Scientific Officer

Officer
9,657 -5.0%
9.94
US$95,965 		9,657 -5.0% 9.94 US$95,965
2026-05-13 2026-05-11 S Sale
2.9
Berkowitz Noah

Chief Medical Officer

Officer
11,108 -5.5%
9.94
US$110,385 		11,108 -5.5% 9.94 US$110,385
2026-05-13 2026-05-11 S Sale
Teel Randy

President and CEO

Executive Director
9,657 -3.3%
9.94
US$95,965 		9,657 -3.3% 9.94 US$95,965
2026-05-08 2026-05-11 PrS Proposed sale
3.1
Andrew Saik

Officer

Officer
11,343
10.11
US$114,678 		11,343 10.11 US$114,678
2026-05-08 2026-05-11 PrS Proposed sale
3.6
Angela Cacace

Officer

Officer
9,834
10.11
US$99,422 		9,834 10.11 US$99,422
2026-05-08 2026-05-11 PrS Proposed sale
2.9
Noah Berkowitz

Officer

Officer
11,312
10.11
US$114,364 		11,312 10.11 US$114,364
2026-05-08 2026-05-11 PrS Proposed sale
Randy Teel

Officer; Director

Executive Director
9,834
10.11
US$99,422 		9,834 10.11 US$99,422
2026-03-19 2026-03-18 S Sale
2.9
Berkowitz Noah

Chief Medical Officer

Officer
6,435 -3.1%
11.10
US$71,431 		6,435 -3.1% 11.10 US$71,431
2026-03-17 2026-03-18 PrS Proposed sale
2.9
Noah Berkowitz

Officer

Officer
6,022
12.01
US$72,324 		6,022 12.01 US$72,324
2026-03-09 2026-03-06 B Purchase
3.3
Morrison Briggs
Non-Executive Director
20,000 +26.3%
13.40
US$268,070 		20,000 +26.3% 13.40 US$268,070
2026-03-02 2026-02-27 S Sale
4.2
Houston John G
Non-Executive Director
11,787 -1.0%
13.14
US$154,881 		11,787 -1.0% 13.14 US$154,881
2026-03-02 2026-02-27 S Sale
4.2
Houston John G
Non-Executive Director
18,822 -1.6%
13.24
US$249,203 		18,822 -1.6% 13.24 US$249,203
2026-03-02 2026-02-27 S Sale
4.2
Houston John G
Non-Executive Director
4,688 -0.4%
13.24
US$62,069 		4,688 -0.4% 13.24 US$62,069
2026-02-27 2026-02-27 PrS Proposed sale
4.2
John G. Houston

former President and CEO; Director

Non-Executive Director
35,297
13.21
US$466,184 		35,297 13.21 US$466,184
2026-02-25 2026-02-23 S Sale
3.8
Loomis David K

Chief Accounting Officer

Officer
1,108 -3.6%
12.16
US$13,473 		1,108 -3.6% 12.16 US$13,473
2026-02-25 2026-02-23 S Sale
3.6
Cacace Angela M

Chief Scientific Officer

Officer
2,571 -1.7%
12.16
US$31,263 		2,571 -1.7% 12.16 US$31,263
2026-02-25 2026-02-23 S Sale
3.6
Cacace Angela M

Chief Scientific Officer

Officer
1,038 -0.7%
12.16
US$12,622 		1,038 -0.7% 12.16 US$12,622
2026-02-25 2026-02-23 S Sale
Teel Randy

President and CEO

Executive Director
3,748 -2.4%
12.16
US$45,576 		3,748 -2.4% 12.16 US$45,576
2026-02-25 2026-02-23 S Sale
Teel Randy

President and CEO

Executive Director
1,038 -0.7%
12.16
US$12,622 		1,038 -0.7% 12.16 US$12,622
2026-02-23 2026-02-23 PrS Proposed sale
3.6
Angela Cacace

Officer

Officer
3,609
12.16
US$43,897 		3,609 12.16 US$43,897
2026-02-23 2026-02-23 PrS Proposed sale
Randy Teel

Officer; Director

Executive Director
4,786
12.16
US$58,213 		4,786 12.16 US$58,213
2026-02-18 2026-02-13 S Sale
Teel Randy

President and CEO

Executive Director
4,403 -2.8%
11.89
US$52,352 		4,403 -2.8% 11.89 US$52,352
2026-02-18 2026-02-13 S Sale
3.1
Saik Andrew

Chief Financial Officer

Officer
5,134 -3.1%
11.89
US$61,043 		5,134 -3.1% 11.89 US$61,043
2026-02-18 2026-02-13 PlS Planned sale
3.6
Cacace Angela M

Chief Scientific Officer

Officer
4,592 -2.9%
11.89
US$54,599 		4,592 -2.9% 11.89 US$54,599
2026-02-18 2026-02-13 S Sale
2.9
Berkowitz Noah

Chief Medical Officer

Officer
5,685 -3.4%
11.89
US$67,595 		5,685 -3.4% 11.89 US$67,595
2026-02-18 2026-02-13 PlS Planned sale
3.8
Loomis David K

Chief Accounting Officer

Officer
1,016 -3.2%
11.89
US$12,080 		1,016 -3.2% 11.89 US$12,080
2026-02-13 2026-02-13 PrS Proposed sale
3.6
Angela Cacace

Officer

Officer
4,592
11.89
US$54,608 		4,592 11.89 US$54,608
2026-02-13 2026-02-13 PrS Proposed sale
3.1
Andrew Saik

Officer

Officer
5,134
11.89
US$61,053 		5,134 11.89 US$61,053
2026-02-13 2026-02-13 PrS Proposed sale
2.9
Noah Berkowitz

Officer

Officer
5,685
11.89
US$67,605 		5,685 11.89 US$67,605
2026-02-13 2026-02-13 PrS Proposed sale
Randy Teel

Officer

Officer
4,403
11.89
US$52,360 		4,403 11.89 US$52,360
2025-11-07 2025-11-07 PlS Planned sale
3.8
Loomis David K

Chief Accounting Officer

Officer
230 -0.7%
9.89
US$2,275 		230 -0.7% 9.89 US$2,275
2025-09-24 2025-09-22 B Purchase
3.3
Morrison Briggs
Non-Executive Director
30,000 +65.2%
7.57
US$227,010 		30,000 +65.2% 7.57 US$227,010
2025-06-24 2025-06-24 S Sale
3.1
Saik Andrew

Chief Financial Officer

Officer
5,700 -3.4%
7.61
US$43,377 		5,700 -3.4% 7.61 US$43,377
2025-06-23 2025-06-24 PrS Proposed sale
3.1
Andrew Saik

Officer

Officer
5,927
7.35
US$43,593 		5,927 7.35 US$43,593
2025-06-18 2025-06-17 S Sale
3.6
Cacace Angela M

Chief Scientific Officer

Officer
2,583 -1.6%
7.49
US$19,347 		2,583 -1.6% 7.49 US$19,347
2025-03-19 2025-03-18 S Sale
2.9
Berkowitz Noah

Chief Medical Officer

Officer
8,658 -7.3%
8.59
US$74,372 		8,658 -7.3% 8.59 US$74,372
2025-03-18 2025-03-18 PrS Proposed sale
2.9
Noah Berkowitz

Officer

Officer
8,658
8.59
US$74,372 		8,658 8.59 US$74,372
2025-02-25 2025-02-24 S Sale
3.6
Cacace Angela M

Chief Scientific Officer

Officer
1,146 -1.2%
16.55
US$18,966 		1,146 -1.2% 16.55 US$18,966
2025-02-25 2025-02-24 S Sale
3.6
Cacace Angela M

Chief Scientific Officer

Officer
3,061 -3.0%
16.75
US$51,272 		3,061 -3.0% 16.75 US$51,272
2025-02-25 2025-02-24 S Sale
4.2
Houston John G

President and CEO

Executive Director
5,154 -0.4%
16.55
US$85,299 		5,154 -0.4% 16.55 US$85,299
2025-02-25 2025-02-24 S Sale
4.2
Houston John G

President and CEO

Executive Director
26,184 -2.2%
16.75
US$438,582 		26,184 -2.2% 16.75 US$438,582
2025-02-25 2025-02-24 S Sale
3.8
Loomis David K

Chief Accounting Officer

Officer
1,214 -6.0%
16.75
US$20,334 		1,214 -6.0% 16.75 US$20,334
2025-02-25 2025-02-24 S Sale
4.1
Taylor Ian

President, R&D

Officer
1,664 -1.0%
16.55
US$27,539 		1,664 -1.0% 16.55 US$27,539
2025-02-25 2025-02-24 S Sale
4.1
Taylor Ian

President, R&D

Officer
7,356 -4.4%
16.75
US$123,213 		7,356 -4.4% 16.75 US$123,213
2025-02-24 2025-02-24 PrS Proposed sale
4.1
Ian Taylor

Officer

Officer
9,020
16.71
US$150,730 		9,020 16.71 US$150,730
2025-02-24 2025-02-24 PrS Proposed sale
4.2
John G Houston

Officer; Director

Executive Director
31,338
16.71
US$523,801 		31,338 16.71 US$523,801
2025-02-24 2025-02-24 PrS Proposed sale
3.6
Angela M Cacace

Officer

Officer
4,207
16.69
US$70,230 		4,207 16.69 US$70,230
2024-11-12 2024-11-07 S Sale
3.8
Loomis David K

Chief Accounting Officer

Officer
231 -2.8%
27.69
US$6,396 		231 -2.8% 27.69 US$6,396
2024-05-20 2024-05-20 PrS Proposed sale
3.8
Sean Cassidy

retired CFO
50,000
33.00
US$1,650,000 		50,000 33.00 US$1,650,000
2024-05-16 2024-05-16 PrS Proposed sale
3.8
Sean Cassidy

retired CFO
35,000
33.00
US$1,155,000 		35,000 33.00 US$1,155,000
2024-05-15 2024-05-15 PrS Proposed sale
3.8
Sean Cassidy

retired CFO
25,000
33.40
US$835,100 		25,000 33.40 US$835,100
2024-05-13 2024-05-13 PrS Proposed sale
3.8
Sean Cassidy

Officer

Officer
15,000
32.00
US$480,000 		15,000 32.00 US$480,000
2024-02-27 2024-02-23 S Sale
3.2
Peck Ronald

Chief Medical Officer

Officer
1,699 -2.5%
47.05
US$79,938 		1,699 -2.5% 47.05 US$79,938
2024-02-27 2024-02-23 S Sale
4.2
Houston John G

President and CEO

Executive Director
5,196 -0.5%
47.05
US$244,472 		5,196 -0.5% 47.05 US$244,472
2024-02-27 2024-02-23 S Sale
3.8
Cassidy Sean A

Chief Financial Officer

Officer
1,702 -0.9%
47.05
US$80,079 		1,702 -0.9% 47.05 US$80,079
2024-02-27 2024-02-23 S Sale
4.1
Taylor Ian

Chief Scientific Officer

Officer
1,701 -1.1%
47.05
US$80,032 		1,701 -1.1% 47.05 US$80,032
2024-11-12 2023-11-08 S Sale
3.8
Loomis David K

Chief Accounting Officer

Officer
229 -2.7%
17.05
US$3,904 		229 -2.7% 17.05 US$3,904
2023-08-14 2023-08-11 S Sale
3.2
Peck Ronald

Chief Medical Officer

Officer
1,324 -4.2%
24.39
US$32,289 		1,324 -4.2% 24.39 US$32,289
2023-03-03 2023-03-01 S Sale
4.2
Houston John G

President and CEO

Executive Director
5,878 -0.6%
29.53
US$173,577 		5,878 -0.6% 29.53 US$173,577
2023-03-03 2023-03-01 S Sale
3.8
Cassidy Sean A

Chief Financial Officer

Officer
1,745 -0.9%
29.53
US$51,530 		1,745 -0.9% 29.53 US$51,530
2023-03-03 2023-03-01 S Sale
4.1
Taylor Ian

Chief Scientific Officer

Officer
1,051 -1.0%
29.53
US$31,036 		1,051 -1.0% 29.53 US$31,036
2022-08-16 2022-08-12 S Sale
3.2
Peck Ronald

Chief Medical Officer

Officer
1,258 -13.4%
68.99
US$86,794 		1,258 -13.4% 68.99 US$86,794
2022-04-18 2022-04-14 PlS Planned sale
3.3
Morrison Briggs
Non-Executive Director
10,754 -35.0%
67.03
US$720,888 		10,754 -35.0% 67.03 US$720,888
2022-04-18 2022-04-14 PlS Planned sale
3.3
Morrison Briggs
Non-Executive Director
7,104 -18.8%
66.07
US$469,356 		7,104 -18.8% 66.07 US$469,356
2022-04-18 2022-04-14 PlS Planned sale
3.3
Morrison Briggs
Non-Executive Director
3,102 -7.6%
65.24
US$202,372 		3,102 -7.6% 65.24 US$202,372
2022-03-15 2022-03-11 PlS Planned sale
3.8
Cassidy Sean A

Chief Financial Officer

Officer
15,000 -8.5%
70.00
US$1,050,000 		15,000 -8.5% 70.00 US$1,050,000
2022-03-04 2022-03-04 S Sale
4.1
Taylor Ian

Chief Scientific Officer

Officer
869 -1.0%
63.94
US$55,564 		869 -1.0% 63.94 US$55,564
2022-03-04 2022-03-04 S Sale
3.8
Cassidy Sean A

Chief Financial Officer

Officer
1,593 -1.0%
63.94
US$101,856 		1,593 -1.0% 63.94 US$101,856
2022-03-04 2022-03-04 S Sale
4.2
Houston John G

President and CEO

Executive Director
6,024 -0.7%
63.94
US$385,175 		6,024 -0.7% 63.94 US$385,175
2022-02-17 2022-02-15 PlS Planned sale
4.1
Taylor Ian

Chief Scientific Officer

Officer
100 -0.1%
76.58
US$7,658 		100 -0.1% 76.58 US$7,658
2022-02-17 2022-02-15 PlS Planned sale
4.1
Taylor Ian

Chief Scientific Officer

Officer
300 -0.4%
75.80
US$22,740 		300 -0.4% 75.80 US$22,740
Explore more

More insider trading research around Arvinas Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America